Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales
18.03.2014 / Fierce Pharma
ThromboGenics admitted last month that slow U.S. sales of its lead drug had put it into a quandary. What could it do to turn the tide? Explore strategic options. Now, the company says sales lagged further for the second half of 2013.